• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Tips on the Doubts about Ketamine/Esketamine

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

Keeping psychiatry honest since 2003.
News and opinions on mental health from Dr. Carlat, the editorial team, and guest contributors.

Tips on the Doubts about Ketamine/Esketamine

August 19, 2020
Ketamine and esketamine have been shown to provide rapid relief of suicidality, however, many lingering doubts have been raised about these medicines. In a previous article from The Carlat Psychiatry Report, Nolan Williams, M.D., discusses the potential negative consequences of ketamine/esketamine treatment. Here are some of Dr. Williams’s tips:

It might have an abuse liability. “There have been cases where patients get exposed to ketamine in an office setting and then start to order it off the internet” (Study Link). “However, ketamine has some promising data as a treatment for addictions, like cocaine and alcohol (Study Link)”. 

Discontinuation may increase suicidality. There were 6 deaths in FDA-registration studies, but it was not statistically significant, therefore, the drug was ultimately approved. “Three of them were definite suicides, and these suicides occurred after their last esketamine dose (Link)”. “Furthermore, the patients who died by suicide had no signs of suicidality in detailed assessments done during the study, which suggests it may have come on during the withdrawal period”.

You need more to prevent a depressive relapse. “So far the only thing that works is more ketamine/esketamine, which raises questions about potential tolerance, withdrawal, and addiction”. Regardless, more studies are needed to determine if these problematic outcomes are due to prolonged ketamine/esketamine treatment.

Abuse can cause bladder inflammation and nerve fibrosis. Ketamine abuse appears to cause “cellular death in the bladder and fibrotic changes in nerves”. This is a significant problem considering that approximately 50% of ketamine abusers are affected (Link). 

Cognitive and neurodegenerative problems. “Long-term ketamine abuse has been associated with cognitive problems and loss of brain tissue in the frontal lobes and left temporoparietal regions (Liao Y et al, Brain 2010;133(7):2115–2122)”. However, ketamine/esketamine may potentially elicit neurotoxic or neuroprotective effects which are believed to be dose-dependent. 

Want to learn more about ketamine/esketamine treatment including the current research being done to address these problematic factors and the known benefits of this treatment? Click Here. Not a subscriber yet? Subscribe now.
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.